West Pharmaceutical Services Q1 Net Income Declines; Increases 2024 Adj. EPS Guidance

(RTTNews) - West Pharmaceutical Services, Inc. (WST) reported that its first quarter net income was $115.3 million, compared to $140.0 million, prior year. Reported EPS was $1.55, declined by 16.2%. Adjusted EPS was $1.56, declined by 21.2%. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $1.26, for the quarter. Analysts' estimates typically exclude special items.

Net sales were $695.4 million, declined 3.0%; organic net sales also declined by 3.0%. Analysts on average had estimated $670.3 million in revenue.

The company reaffirmed 2024 net sales guidance in a range of $3.000 billion to $3.025 billion. The company increased full-year 2024 adjusted EPS guidance to a new range of $7.63 to $7.88, compared to a prior range of $7.50 to $7.75. Analysts expect the company to report profit per share of $7.62.

The company also announced that its Board of Directors has approved a third-quarter 2024 dividend of $0.20 per share. The dividend will be paid on August 7, 2024, to shareholders of record as of July 31, 2024.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.